Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Evaluation Of Orphan & Pediatric Legislation Nears Completion

Focus Is On Incentives & Access As Needs Remain Unmet

Executive Summary

Spring 2020 should see the publication of a working document by the European Commission on how to improve the operation of the EU legislation on orphan and pediatric medicines. The commission has asked for more input from member state experts.

You may also be interested in...



EU Filings For Orphan Status On The Decline

Requests from sponsors for orphan drug status in the EU are showing a downward trend. It is not yet clear why, but a forthcoming report from the European Commission may provide some answers.

New EU Commissioner Outlines Plans To Tackle Shortages

The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.

EU Report Probes Impact Of IP Incentives On R&D, Market Access

A report for the European Commission’s analysis of pharmaceutical IP incentives finds that the effective protection period has declined over 20 years, but delays to generic entry are still putting pressure on pharmaceutical spending.

Related Content

Topics

UsernamePublicRestriction

Register

PS141403

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel